90002-36-1

Basic information

• Product Name: 2-ETHYLPHENYLBORONIC ACID
• Synonyms: 2-ETHYLPHENYLBORONIC ACID;2-ETHYLBENZENEBORONIC ACID;AKOS BRN-0241;O-ETHYLPHENYLBORONIC ACID;2-Ethylbenzeneboronic acid, 98+%;2-Ethylphenylboronic Acid (contains varying amounts of Anhydride);boronic acid, (2-ethylphenyl)-;2-ETHYLPHENYLBORONIC
• CAS NO: 90002-36-1
• Molecular Formula: C₈H₁₁BO₂
• Molecular Weight: 149.98
• Product Categories: Boronic acids;Aryl;Boronic acid;Organoborons;Boronic Acids;Boronic Acids and Derivatives;Boronate Ester;Potassium Trifluoroborate
• Mol File: 90002-36-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 102.5-107.5 °C(lit.)
• Boiling Point: 299.1 °C at 760 mmHg
• Flash Point: 134.7 °C
• Appearance: /
• Density: 1.07 g/cm³
• Vapor Pressure: 0.000544mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 8.61±0.58(Predicted)
• BRN: 2963801
• CAS DataBase Reference: 2-ETHYLPHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ETHYLPHENYLBORONIC ACID(90002-36-1)
• EPA Substance Registry System: 2-ETHYLPHENYLBORONIC ACID(90002-36-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37-37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 90002-36-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C8H11BO2/c1-2-7-5-3-4-6-8(7)9(10)11/h3-6,10-11H,2H2,1H3

Upstream product

• 109-72-8 n-butyllithium 
• 150-46-9 triethyl borate 
• 1973-22-4 1-bromo-2-ethylbenzene 
• 103-63-9 1-phenyl-2-bromoethane 

Downstream Products

• 105337-78-8 ethyl 2-(2-ethylphenyl)acetate 
• 1269525-54-3 1-(2-ethylphenyl)-1,9-dihydro[60]fullerene 
• 1335222-90-6 C₁₇H₁₈N₄ 
• 1309435-09-3 (S)-3-(2-ethylphenyl)cyclohexanone 
• 1310064-12-0 C₂₉H₂₉N₅O 
• 1112196-99-2 9-(2-ethylphenyl)anthracene 
• 1308652-73-4 9-(2-ethylphenyl)acridine 
• 1244469-06-4 6-isopropyl-4-(2-ethylphenyl)-2H-cromen-2-one 
• 683238-57-5 2-ethyl-2'-nitro-biphenyl 

Relevant articles and documents

Aryl boronic acid preparation method

The invention belongs to the technical field of fine chemical engineering, and relates to an aryl boronic acid preparation method. In the prior art, aryl boronic acid as a novel safe and environmentally-friendly arylation reagent is widely used in scientific research and production of various fine chemicals containing aryl structures in the fields of medicines, pesticides, advanced materials and the like; and the aryl boronic acid compound preparation method reported in the disclosed literature has problems of harsh reaction conditions and high cost. A purpose of the invention is to provide amethod, wherein an aryl boron compound is formed by carrying out a reaction on a Grignard reagent and trialkyl borate under mild conditions, the composition of the aryl boron compound is converted from the main component diaryl borate into the main component aryl borate, and the aryl borate is hydrolyzed to obtain aryl boric acid, so that the preparation cost of the acyl aryl boric acid compound can be remarkably reduced, and the method has good practical application prospect.

Structure, conformation, and dynamic processes of the stereolabile atropisomers of hindered terphenyl hydrocarbons

(Chemical Equation Presented) Ortho-substituted p-terphenyl hydrocarbons exist as trans and cis atropisomers that were identified by low-temperature NMR spectroscopy. The interconversion barriers increase with the dimensions of the ortho substituents, the experimental values being matched by ab initio calculations. X-ray diffraction shows that only the trans atropisomer is present in the solids. Spectra of a tert-butyl derivative in nonequilibrium conditions indicate that the cis is more populated than the trans atropisomer in solution, favored by attractive interactions.

Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions

The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activ